logo
  

Krispy Kreme Q1 Loss Widens, Adj. EPS Beats View; Backs FY24 Outlook

Donut chain Krispy Kreme, Inc. (DNUT) reported Thursday that its first-quarter net loss attributable to the company was $8.5 million, wider than last year's loss of $0.3 million.

Loss per share was $0.05, compared to $0.00 a year ago.

Adjusted earnings per share were $0.07, compared to prior year's $0.09.

Net revenue grew 5.7 percent to $442.7 million from $419.0 million last year. Organic revenue grew 6.7 percent to $440.9 million.

Analysts on average expected the company to report earnings of $0.06 per share on revenues of $434.1 million, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

Looking forward to fiscal 2024, the company continues to expect adjusted earnings per share between $0.27 and $0.31, net revenue growth of 5 percent and 7 percent and organic revenue growth of 6 percent to 8 percent.

The Street view for earnings is $0.28 per share for the year.

In pre-market activity on the Nasdaq, Krispy Kreme shares were gaining around 2.3 percent to trade at $13.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT